Experimental Protocols
For the I Na experiments HEK-293 cells stably transfected with hNaV1.5 cDNA were continuously maintained in a humidified, gassed (∼5% CO 2 ) incubator at approximately 37℃, and passaged using Dulbecco's Modified Eagle Medium (DMEM) supplemented with 10% foetal bovine serum, 1% non-essential amino acids, 1% penicillin/streptomycin and 0.4 mg/mL geneticin. For the I CaL experiments myocytes were isolated enzymatically from guinea-pig ventricle as previously described 21 . Briefly, male guinea-pigs were killed by cervical dislocation following stunning. Myocytes were isolated after perfusion of the heart with a physiological salt solution containing reduced calcium and 0.8 mg/mL of collagenase Type 1 (Worthington Biochemicals). Cells were stored at room temperature in Dulbecco's MEM (Life Technologies, Scotland) and used for electrophysiological investigation on the day of preparation. For the I Kr experiments HEK-293 cells stably transfected with hERG cDNA were obtained from the University of Wisconsin. The cells were continuously maintained in, and passaged, using minimum essential medium supplemented with 10% foetal bovine serum, 1% non-essential amino acids, 1% sodium pyruvate, 1% penicillin/Streptomycin and 0.4 mg/ml geneticin. The cells were seeded onto glass coverslips in 35 mm 2 dishes (containing 3 ml medium without geneticin) at a density that enabled isolated cells to be selected for patch-clamping.
The conventional whole-cell patch-clamp configuration was used to record membrane currents at room tem- The voltage protocols for studying the concentration-dependent effect of the compounds on peak current were as follows. For I Na , a step from −100 mV (holding potential) to −30 mV for 20 ms, then step back to a holding potential of −100 mV. For I CaL , a step from −40 mV (holding potential) to 0 mV for 400 ms, and then stepped back to the holding potential of −40 mV. The pulses were applied at frequencies of 0.1 and 0.2 Hz for I Na and I CaL respectively. Peak I Na was measured with respect to the holding current measured at −100 mV just before
In this section we describe the three protocols under which the models were used to simulate cellular responses, and state the model outputs that we have taken as potential in-silico risk indicators. We correlated these markers against the TdP risk categories as described in section 2.4 of the main text and section 3.1 of this document, in order to establish those markers that provided an indication of risk.
Firstly, we considered the membrane voltage under regular pacing. Models were paced at 1Hz for 1000 seconds in order to obtain an approximately steady behaviour. The final AP was analysed and the maximum upstroke velocity (proportional to peak current), peak membrane voltage, and APD at 50% and 90% repolarisation were recorded, along with APD90 minus APD50 as measure of 'triangulation'. The cytosolic calcium transient corresponding to this AP was also analysed; peak calcium, 50% duration, 90% duration and triangulation of the transient were recorded.
Secondly, the S1-S2 restitution protocol, was performed on the models. 1Hz was chosen as the S1 pacing frequency and the models were again paced for 1000 seconds in order to obtain a steady state before the protocol began. Results were analysed to determine the maximum slope of the restitution curve.
Finally, a dynamic restitution protocol was performed. This consisted of 100 paces at varying frequencies from 1Hz up to 10Hz. The final eight action-potential traces at each frequency were analysed to detect voltage alternans and the frequency at which depolarisation occurred before 90% repolarisation had completed (i.e.
the frequency at which non-spontaneous EADs were induced), the highest pacing cycle length at which either occurred was recorded as the 'instability onset'. The maximum slope of the dynamic restitution curve was recorded. The area between the control and drug-blocked dynamic restitution curves was also recorded; this measure is intended to quantify the change in APD over a range of pacing frequencies.
The full list of the 15 simulated markers is:
1. Steady-State 1Hz pacing
• APD90
• APD50
• APD Triangulation
• Peak membrane voltage
• Maximum upstroke velocity
• Ca duration 90
• Ca duration 50
• Ca triangulation
• Peak Ca 2. S1-S2 Restitution
• Maximum slope
Dynamic Restitution
• Alternans onset pacing frequency
• (non-spontaneous) EAD onset frequency
• Instability onset frequency
• Area between control and drug curves
The tolerances of CVODE were set as: relative, 10 −5 ; absolute, 10 −7 . The simulations involved in determining the 1Hz APD90 for the Grandi et al. model for a compound at a particular concentration, and the subsequent classification of the compound into a risk category, can be completed in under one minute on a single core of a desktop PC (an Intel Core2 Duo 3GHz desktop PC was used). We propose that the calculation be performed for a range of concentrations, informing the therapeutic doses at which the compound may be used safely.
Details of Statistical Methods
In this section we provide more details on the statistical methods used to evaluate the predictive power of the different markers. Section 3.1 provides details of the implementation of the LDA technique, and section 3.2 provides details of validation techniques used to ensure that the predictive power of our markers was not down to chance.
Linear Discriminant Analysis Implementation
We assemble a large matrix of training data X from distinct categories k = 1 . . . K (in our case K = 4 -the number of risk categories after combining 1 and 2 due to their equal risk). Each row i of X represents a drug, and each column j contains a 'discriminant variable' -one of our measures (e.g. hERG IC50 or simulated APD90 from a particular model). Here we follow the notation of Hastie et al. 80 , to whom we refer the interested reader to their section 4.3 for a full derivation of this technique.
Our prior distributions (the likelihood that a drug belongs to a particular category) are set equal and given as
If the mean value of our measures for the training points in category k is denoted by the vector µ k , then the 'pooled' or 'common' covariance matrix is given by
where N is the total number of drugs and X i is a vector of measures for a particular drug. The linear discriminant functions for each category are then given by
A new observation y is then classified to the category k for which the discriminant function δ k (y) is largest.
Notice that for the 1D markers presented in the main text X k is a column vector. We demonstrate briefly how this method works in Figure S1 .
In the bottom panel of Figure S1 we see a set of training data from four distinct categories, distributed along a one dimensional variable 'y'. LDA is derived based on the assumption that the training data in each category are normally distributed, with each category having a different mean but a common covariance matrix. Our dataset is not large enough to test whether the points in each category follow a normal distribution, yet in practice LDA has been found to work well for many distributions 80 . LDA then uses maximum likelihood estimates to calculate the probability of each point in y-space being a member of each category. The resulting probability of an unseen observation belonging to each of the categories is shown in the top panel of Figure S1 . To classify an unseen observation we simply assign it to the category with the highest probability at that point. (or equivalently probability) at that point.
Cross-validation
Despite the fact that the errors in classification as shown in Figure 4 of the main text are entirely independent of the training data (because of the N-fold cross validation/'leave-one-out validation'), a possible criticism of our approach would be that we tried many different markers, and the success of the best-performing one was purely by chance. We have evaluated the predictive power that such 'random guesses' for the categories would provide. In Figure S2 we plot the resulting error for 1,000; 10,000; 100,000 and 1,000,000 random guesses: none of the resulting errors are as small as those of the simulated marker suggested in the main text. This finding suggests that the measure has strong predictive power and has not been successful 'by chance'.
The fact that the distribution shown in Figure 5 in the main text shows a clear bias towards "being predictive", rather than "being random" (as plotted in Figure S2 ) provides further evidence that our approach is indeed producing predictive power and our findings are not a chance result. Indeed the 30 "most predictive" markers listed in Supplementary Material 4, and shown in bold on Figure 5 of the main text, are all multi-channel markers. None of the hERG-only markers were as accurate, providing further evidence that the multichannel simulations are not outperforming the existing measures by chance.
Yet, we acknowledge that the choice of best marker was strongly dependent on the dataset. In order to ascertain whether our measure of Grandi et al. 26 APD90 was robust to the different datasets of drugs we split them into separate groups for K-fold cross validation of the marker choice. Although Hastie et al. 80 suggest that K is generally taken to be between 5 and 10 we use K = 4 because we only have four drugs in category 2. These groups were chosen so that each contained roughly equal numbers of drugs from each of the risk categories (as shown in brackets after the drug name). The stratified training datasets were then formed by 'leave-onegroup-out': so stratification set 1 was formed from groups 2, 3, 4, stratification set 2 from groups 1, 3, 4 etc. This was necessary to ensure that each risk category contained a number of points with which to 'train' the LDA method.
The method referred to in the main text (individual 'leave-one-out' for each compound, LDA, and finally classification) was then performed for each of these stratified training datasets. We subsequently ranked the predictive power of each marker in each of the training datasets.
In Figure S3 we present the same data as in the main text's Figure 5 for each of the stratified datasets. The top 30 markers for the full dataset are again shown in bold. We see that the most predictive measures are relatively robust across the different stratifications, and in particular our best measure Grandi et al. In addition to the experiment displayed in the main text we also performed a 2D LDA analysis for every combination of the 761 1D markers (289180 in total). The result of this was a slight improvement over the 1D markers (as shown in Figure S4 ), but a possible loss of consistency between stratified groups as shown in Figure S5 (it is possible that out of so many markers "predictive" ones appear by chance, as shown in Figure 2(c) for 100,000 random category guesses). For this reason the main text refers only to the more robust 1D markers. 
Most predictive markers
The 30 most predictive markers resulting from the LDA leave-one-out trial are shown in Table S1 . Notice that all are from multi-channel block simulations, and the majority are measures associated with AP prolongation.
All of these markers provide risk predictions which have less than half of the error in classification that the current best-practise marker exhibits, as shown in Figure 5 of the main text. Table S1 : The 30 most predictive 1D measures, as highlighted in bold in Figure 5 of the main text. All are multi-channel simulated markers.
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The errors in Table S2 resulted from leave-one-out, linear discriminant analysis, when classifying according to 
